HLN
Haleon plc (NYSE)
Healthcare — Drug Manufacturers - Specialty & Generic
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
Price History
Fundamentals
| Market Cap | $41.40B |
| P/E Ratio (TTM) | 19.18 |
| Forward P/E | 15.55 |
| EPS (TTM) | $0.49 |
| Dividend Yield | 2.05% |
| Profit Margin | 15.11% |
| Revenue Growth | 0.60% |
| ROE | 10.27% |
| Debt/Equity | 52.37 |
| Recommendation | Buy 2.2 |
| Analyst Target | $11.69 |
| Analysts | 5 |
| Indexes | NYSE |
Technical Indicators
| RSI (14) | 61.3 |
| Beta | 0.25 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $11.28 |
| 52-Week Low | $8.65 |
| 50-Day Avg | $9.16 |
| 200-Day Avg | $9.69 |
| Avg Volume | $8.98M |
| Volume | $8.34M |
Performance Analysis
BULLISHHLN shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:13 UTC
Back to Screener Export Report